According to a filing by CSPC Pharmaceutical Group Ltd. to the Hong Kong stock exchange, the first emergency authorization has been granted to China for a homegrown mRNA COVID vaccination. The vaccine uses the same technology that was used in the U.S. by Pfizer PFE (-0.37%) and BioNTech BNTX (+0.95%) and Moderna respectively. It is designed to attack both the older and newer versions of the virus. China relied on inactivated vaccines to protect its people during the pandemic. However, as the virus spread and became more common, the West’s vaccines were less effective than those made by China.